Skip to main content

April 2022

CORP 2022 - 043 - Information regarding Jakavi and treatment of myelofibrosis within Velindre
CORP 2022 - 044 - Information with regards to Melanoma
CORP 2022 - 045 - Information regarding the treatment of Breast Cancer within Velindre
CORP 2022 - 046 - Information regarding the treatment of Lung Cancer within Velindre
CORP 2022 - 047 - Information in relation to rostering software
CORP 2022 - 048 - Information in relation to waiting lists, COVID and HAI's
CORP 2022 - 049 - Information relating to spending on communications, public relations, digital and other similar activities
CORP 2022 - 050 - Information regarding patient treatment with Nivolumab within Velindre
CORP 2022 - 052 - Information regarding Clinical Imaging Modalities data within Velindre
CORP 2022 - 053 - Information relating to Physiotherapy Services
CORP 2022 - 054 - Information regarding Peritoneal Cancer Funding for Cytoreductive Surgery and HIPEC in Wales
CORP 2022 - 055 - Information in relation to physiotherapy services at Velindre
CORP 2022 - 056 - Information in relation to incidence and treatment of CLL and MCL at Velindre